Camlin Fine Sciences Limited (CAMLINFINE) AI Stock Analysis

• Market Cap: ₹39.92B
• Dividend Yield: N/A
• Average Volume (3M): 37.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: 8.06%
• EPS Growth: 19.90%
• Country: IN
• Employees: 624
• Sector: Basic Materials
• Sector Strength: 66
• Industry: Chemicals - Specialty
• EPS (TTM): 0.20
• Shares Outstanding: 187,921,000
• 10 Day Avg. Volume: 26,330
• 30 Day Avg. Volume: 37,454
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹248.00
• Price Target Upside: 21.87% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: ₹248.00 ▲(21.87% Upside)

Camlin Fine Sciences Limited's overall stock score is primarily impacted by its weak financial performance and poor valuation. The technical analysis suggests bearish momentum, further weighing down the score. The absence of earnings call insights and corporate events leaves the financial and technical aspects as the main determinants of the score.

Camlin Fine Sciences Limited Business Overview & Revenue Model

Company Description

Camlin Fine Sciences Limited (CAMLINFINE) is a leading global player in the field of specialty chemicals, providing high-quality ingredients and solutions primarily for the food, feed, and industrial sectors. The company offers a wide range of products including antioxidants, aroma chemicals, and performance chemicals, which are integral to food preservation, flavor enhancement, and industrial applications.

How the Company Makes Money

Camlin Fine Sciences Limited generates revenue through the sale of its specialty chemicals, which are categorized into three main segments: food antioxidants, aroma chemicals, and performance chemicals. The company earns money primarily by supplying these products to various industries such as food and beverages, animal nutrition, and industrial applications. Their key revenue streams include the sale of antioxidants used in food preservation, which helps extend the shelf life of products, and aroma chemicals used in enhancing flavors and fragrances. Significant partnerships with global distributors and end-users, along with a focus on research and development, contribute to the company's earnings by enabling innovation and expansion into new markets.

Camlin Fine Sciences Limited Financial Statement Overview

Summary

Camlin Fine Sciences Limited shows modest revenue growth but faces significant profitability challenges, with consistent net losses and negative cash flow. The balance sheet is stable with moderate leverage, yet cash constraints are evident.

Income Statement

The revenue growth over the last year was modest at 4.48%. However, the company has struggled with profitability, as indicated by a negative net profit margin of -8.34% for the latest year. This marks a deterioration from the previous year's margin, which was also negative. Gross profit margins have improved slightly, but overall profitability remains weak, evidenced by negative net income for the past two years.

Balance Sheet

The debt-to-equity ratio is approximately 0.76, indicating a moderate level of leverage. Return on equity has turned negative due to the recent net losses, which is concerning. However, the equity ratio is relatively strong at 44.53%, providing some asset coverage. The balance sheet indicates stability in the asset base but highlights challenges in profitability.

Cash Flow

Operating cash flow has significantly decreased from the previous year. Free cash flow has turned negative, reflecting challenges in generating cash relative to capital expenditures. The operating cash flow to net income ratio is positive, suggesting operational activities are still generating cash, but the free cash flow to net income ratio is negative, highlighting cash constraints.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.67B	16.67B	15.95B	16.71B	14.04B	11.81B
Gross Profit	8.17B	8.17B	6.58B	8.27B	6.34B	5.77B
EBITDA	2.47B	2.18B	487.60M	1.84B	1.79B	1.89B
Net Income	-1.39B	-1.39B	-927.53M	521.06M	606.78M	509.63M
Balance Sheet
Total Assets	20.24B	20.24B	19.52B	20.60B	18.00B	14.82B
Cash, Cash Equivalents and Short-Term Investments	1.92B	1.92B	812.28M	951.90M	1.29B	1.21B
Total Debt	6.81B	6.81B	6.83B	8.01B	6.46B	5.50B
Total Liabilities	11.49B	11.49B	10.95B	12.36B	10.35B	7.68B
Stockholders Equity	9.02B	9.02B	8.65B	8.19B	7.48B	6.43B
Cash Flow
Free Cash Flow	0.00	-157.24M	784.06M	-934.11M	-683.40M	335.07M
Operating Cash Flow	0.00	267.23M	1.39B	508.98M	1.45B	1.17B
Investing Cash Flow	0.00	-753.50M	-664.98M	-1.25B	-2.49B	-1.33B
Financing Cash Flow	0.00	724.43M	-859.72M	596.58M	1.36B	386.27M

Camlin Fine Sciences Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 203.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAMLINFINE, the sentiment is Neutral. The current price of 203.5 is below the 20-day moving average (MA) of 215.95, below the 50-day MA of 260.65, and above the 200-day MA of 188.46, indicating a neutral trend. The MACD of -13.50 indicates Negative momentum. The RSI at 39.98 is Neutral, neither overbought nor oversold. The STOCH value of 51.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:CAMLINFINE.

Camlin Fine Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADVENZYMES	73 Outperform	₹37.92B	27.71		1.54%	5.89%	-1.30%
ROSSARI	69 Neutral	₹34.85B	26.03		0.08%	11.77%	-1.14%
PREMEXPLN	63 Neutral	₹28.99B	78.54		0.10%	62.92%	34.04%
Sector *	62 Neutral	$10.28B	6.21	0.76%	2.84%	3.10%	-36.03%
BALAMINES	59 Neutral	₹48.85B	32.50		0.72%	-12.28%	-22.10%
NEOGEN	51 Neutral	₹38.91B	115.84		0.14%	11.14%	-11.15%
CAMLINFINE	43 Neutral	₹39.92B	―		―	8.06%	19.90%